Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
Academic rigor, journalistic flair
Articles on Health Canada drug approval
Displaying all articles
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
An infectious diseases doctor reviews the evidence, discusses hesitancy and concerns about side-effects and explains the overwhelming case for vaccinating five-to-11-year-olds, including his own son.
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
Top contributors
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Philosophy and Core Member of the Rotman Institute of Philosophy, Western University
-
Associate Professor, Infectious Diseases, University of Saskatchewan
-
Assistant Professor, Department of Family and Community Medicine, University of Toronto
